Global Companion Diagnostic Tests in Oncology Market Growth (Status and Outlook) 2023-2029

Global Companion Diagnostic Tests in Oncology Market Growth (Status and Outlook) 2023-2029

Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer.

LPI (LP Information)' newest research report, the “Companion Diagnostic Tests in Oncology Industry Forecast” looks at past sales and reviews total world Companion Diagnostic Tests in Oncology sales in 2022, providing a comprehensive analysis by region and market sector of projected Companion Diagnostic Tests in Oncology sales for 2023 through 2029. With Companion Diagnostic Tests in Oncology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Companion Diagnostic Tests in Oncology industry.

This Insight Report provides a comprehensive analysis of the global Companion Diagnostic Tests in Oncology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Companion Diagnostic Tests in Oncology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Companion Diagnostic Tests in Oncology market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Companion Diagnostic Tests in Oncology and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Companion Diagnostic Tests in Oncology.

The global Companion Diagnostic Tests in Oncology market size is projected to grow from US$ 3814.3 million in 2022 to US$ 7364.7 million in 2029; it is expected to grow at a CAGR of 9.9% from 2023 to 2029.

United States market for Companion Diagnostic Tests in Oncology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Companion Diagnostic Tests in Oncology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Companion Diagnostic Tests in Oncology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Companion Diagnostic Tests in Oncology players cover Abbott, Roche, Genomic Health, QIAGEN, Agilent, Agendia, BioMerieux, Illumina and Siemens Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Companion Diagnostic Tests in Oncology market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Protein Detection
DNA Detection

Segmentation by application
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Roche
Genomic Health
QIAGEN
Agilent
Agendia
BioMerieux
Illumina
Siemens Healthcare
Thermo Fisher

Please note: The report will take approximately 2 business days to prepare and deliver.